Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years old with informed consent~2. Histologically (preferred) or radiologically confirmed distal malignant bile duct tumors~3. Inoperability by staging, comorbidities or patient wishes~4. Distal tumors 2cm away from the portal hilum~5. Bilirubin \> 50umol/L at diagnosis~Exclusion Criteria:~1. Periampullary tumours~2. Multiple hepatic metastases with significant blockage of one or more liver segments (if no segment blockage, metastasis is not an exclusion criteria)~3. Presence of main portal vein thrombosis~4. Prior SEMS placement~5. Prior Billroth II or roux-en Y reconstruction~6. History of bleeding disorder or use of anticoagulation~7. Child's B/C cirrhosis~8. Pregnancy~9. Performance status ECOG ≥3 (confined to bed / chair \> 50% waking hours)~10. Presence of other malignancy~11. Presence of gastric outlet obstruction~12. Life expectancy \< 3months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SEMS only (Type: ACTIVE_COMPARATOR): Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) would be inserted to bypass the site of narrowing (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea)
- EBRFA and SEMS (Type: ACTIVE_COMPARATOR): Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The radiofrequency ablation (EBRFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter with energy delivered by an RFA generator would be used to apply RFA to the entire length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. Patients would undergo 2 sessions of EBRFA 2 weeks apart. A plastic stent would be inserted in between the 2 sessions. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after the second EBRFA.

Based on this trial design, predict the completion outcome and termination type (if applicable).